Latest news

• Daiichi gets breakthrough status for pre-NDA leukaemia drug

  Quizartinib could have an advantage over rival drug Rydapt. Daiichi Sankyo is gearing up to file its acute myeloid leukaemia (AML) treatment quizartinib in the US, and could now get a ... The data suggest that quizartinib could have an advantage over the

• Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

  While Bluebird Bio impressed with further strong data on beta thalassemia and sickle cell disease on Friday, the following day saw Novartis and Celgene both unveil longer-term data in DLBCL – ... These results give it the edge over the only other

• Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

  NICE looks set to recommend another AML treatment, Novartis’ Rydapt (midostaurin), which is for newly diagnosed acute FLT3-mutation-positive myeloid leukaemia.

• FDA fast-tracks Astellas' Rydapt rival

  Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival Novartis’ budding $250m-plus product Rydapt (midostaurin). ... If approved, the Japanese pharma group would see its drug not

• Novartis gets EU nod for leukaemia drug Rydapt

  The FLT3 inhibitor adds to its US approval in AML. Novartis has added EU approval its US registration for FLT3 inhibitor Rydapt, a new drug that brings years of stagnation in ... Novartis is proud that we can deliver Rydapt, a breakthrough medicine, to